NASDAQ:CSBRChampions Oncology Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Champions Oncology Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $9.84 +0.15 (+1.55 %) (As of 06/4/2020 04:00 PM ET) Add Compare Share Today's Range$9.66Now: $9.84▼$9.9850-Day Range$6.87MA: $8.44▼$9.6352-Week Range$4.02Now: $9.84▼$10.44Volume43,400 shsAverage Volume32,144 shsMarket Capitalization$116.98 millionP/E RatioN/ADividend YieldN/ABeta1.3 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The company also offers POS products, including personalized tumor boards that are designed to provide access to oncologists with expertise in particular tumor types; and provides access to gene sequencing that analyzes the genetic makeup of patient's tumor for the purpose of identifying potentially useful drugs. In addition, it offers Translational Oncology Solutions, including a preclinical Tumorgraft platform to pharmaceutical and biotechnology companies. Champions Oncology, Inc. markets its products through Internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011 to reflect its new focus on developing technologies to personalize the development and use of oncology drugs. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.Read More Beat the Market (BTM) Rank™ 1.3 Analyst's Opinion Consensus RatingChampions Oncology has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.13, Champions Oncology has a potential upside of 2.9% from its current price of $9.84.Amount of Analyst CoverageChampions Oncology has received no research coverage in the past 90 days. Previous Next 2.2 Community Rank Outperform VotesChampions Oncology has received 143 “outperform” votes. (Add your “outperform” vote.)Underperform VotesChampions Oncology has received 180 “underperform” votes. (Add your “underperform” vote.)Community SentimentChampions Oncology has received 55.73% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Champions Oncology and other stocks. Vote “Outperform” if you believe CSBR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CSBR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldChampions Oncology does not currently pay a dividend.Dividend GrowthChampions Oncology does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Champions Oncology insiders have sold 64,115.81% more of their company's stock than they have bought. Specifically, they have bought $7,709.00 in company stock and sold $4,950,397.00 in company stock.Percentage Held by Insiders44.30% of the stock of Champions Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.44% of the stock of Champions Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Champions Oncology are expected to grow by 400.00% in the coming year, from $0.02 to $0.10 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Champions Oncology is -327.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Champions Oncology is -327.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChampions Oncology has a P/B Ratio of 51.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.3Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.48 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CSBR Previous Symbol CUSIPN/A CIK771856 Webwww.championsoncology.com Phone201-808-8400Debt Debt-to-Equity Ratio1.04 Current Ratio0.96 Quick Ratio0.96Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio492.00 P/E GrowthN/A Sales & Book Value Annual Sales$27.07 million Price / Sales4.32 Cash Flow$0.06 per share Price / Cash Flow153.34 Book Value$0.19 per share Price / Book51.79Profitability EPS (Most Recent Fiscal Year)$0.01 Net Income$130,000.00 Net Margins-0.58% Return on Equity-7.73% Return on Assets-1.33%Miscellaneous Employees92 Outstanding Shares11,888,000Market Cap$116.98 million Next Earnings Date7/20/2020 (Estimated) OptionableNot Optionable NASDAQ:CSBR Rates by TradingView Receive CSBR News and Ratings via Email Sign-up to receive the latest news and ratings for CSBR and its competitors with MarketBeat's FREE daily newsletter. Champions Oncology (NASDAQ:CSBR) Frequently Asked Questions How has Champions Oncology's stock been impacted by COVID-19 (Coronavirus)? Champions Oncology's stock was trading at $4.97 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CSBR stock has increased by 98.0% and is now trading at $9.84. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Champions Oncology? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Champions Oncology in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Champions Oncology. When is Champions Oncology's next earnings date? Champions Oncology is scheduled to release its next quarterly earnings announcement on Monday, July 20th 2020. View our earnings forecast for Champions Oncology. How were Champions Oncology's earnings last quarter? Champions Oncology Inc (NASDAQ:CSBR) posted its earnings results on Thursday, March, 12th. The biotechnology company reported $0.03 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.02 by $0.01. The biotechnology company had revenue of $9.01 million for the quarter, compared to the consensus estimate of $8.07 million. Champions Oncology had a negative net margin of 0.58% and a negative return on equity of 7.73%. View Champions Oncology's earnings history. What price target have analysts set for CSBR? 3 brokerages have issued 1-year target prices for Champions Oncology's shares. Their forecasts range from $9.25 to $11.00. On average, they expect Champions Oncology's stock price to reach $10.13 in the next year. This suggests a possible upside of 2.9% from the stock's current price. View analysts' price targets for Champions Oncology. Has Champions Oncology been receiving favorable news coverage? Press coverage about CSBR stock has been trending somewhat negative on Thursday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Champions Oncology earned a coverage optimism score of -1.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutChampions Oncology. Who are some of Champions Oncology's key competitors? Some companies that are related to Champions Oncology include Voyager Therapeutics (VYGR), Harpoon Therapeutics (HARP), Precision BioSciences (DTIL), PDL BioPharma (PDLI), Verona Pharma (TARA), Eiger Biopharmaceuticals (EIGR), Tcr2 Therapeutics (TCRR), CASI Pharmaceuticals (CASI), Cellular Biomedicine Group (CBMG), ADMA Biologics (ADMA), Brainstorm Cell Therapeutics (BCLI), Sutro Biopharma (STRO), Gritstone Oncology (GRTS), Axcella Health (AXLA) and Cabaletta Bio (CABA). View all competitors. What other stocks do shareholders of Champions Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Champions Oncology investors own include Gilead Sciences (GILD), Cytosorbents (CTSO), Corbus Pharmaceuticals (CRBP), Crispr Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), AbbVie (ABBV), Agile Therapeutics (AGRX), Cronos Group (CRON), Mesoblast (MESO) and NovaBay Pharmaceuticals (NBY). Who are Champions Oncology's key executives? Champions Oncology's management team includes the following people: Dr. Ronnie Morris, CEO & Director (Age 53)Mr. David Barry Miller, Chief Financial Officer (Age 50)Dr. Philip P. Breitfeld, Chief Strategy & Innovation Officer and Director (Age 66)Mr. Mark Weinstein, Chief Information OfficerMr. Bruce Ruggeri, Chief Scientific Officer What is Champions Oncology's stock symbol? Champions Oncology trades on the NASDAQ under the ticker symbol "CSBR." Who are Champions Oncology's major shareholders? Champions Oncology's stock is owned by many different institutional and retail investors. Top institutional investors include NEA Management Company LLC (14.42%), Cowen Prime Services LLC (2.52%), Cadence Capital Management LLC (1.87%), Essex Investment Management Co. LLC (1.43%), BlackRock Inc. (1.24%) and Millrace Asset Group Inc. (0.69%). Company insiders that own Champions Oncology stock include Daniel Newman Mendelson, Enterprise Associates 14 New, Joel Ackerman and Ronnie Morris. View institutional ownership trends for Champions Oncology. Which major investors are selling Champions Oncology stock? CSBR stock was sold by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc., Millrace Asset Group Inc., Cadence Capital Management LLC, Essex Investment Management Co. LLC, ClariVest Asset Management LLC, and Alambic Investment Management L.P.. Company insiders that have sold Champions Oncology company stock in the last year include Enterprise Associates 14 New, and Ronnie Morris. View insider buying and selling activity for Champions Oncology. Which major investors are buying Champions Oncology stock? CSBR stock was acquired by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Cowen Prime Services LLC, Globeflex Capital L P, Invesco Ltd., BlackRock Inc., and Morgan Stanley. Company insiders that have bought Champions Oncology stock in the last two years include Daniel Newman Mendelson, and Ronnie Morris. View insider buying and selling activity for Champions Oncology. How do I buy shares of Champions Oncology? Shares of CSBR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Champions Oncology's stock price today? One share of CSBR stock can currently be purchased for approximately $9.84. How big of a company is Champions Oncology? Champions Oncology has a market capitalization of $116.98 million and generates $27.07 million in revenue each year. The biotechnology company earns $130,000.00 in net income (profit) each year or $0.01 on an earnings per share basis. Champions Oncology employs 92 workers across the globe. What is Champions Oncology's official website? The official website for Champions Oncology is www.championsoncology.com. How can I contact Champions Oncology? Champions Oncology's mailing address is One University Plaza Suite 307, Hackensack NJ, 07601. The biotechnology company can be reached via phone at 201-808-8400 or via email at [email protected] This page was last updated on 6/4/2020 by MarketBeat.com Staff
